Company: JUNS
Filing Date: 2025-10-28
Form Type: PRER14A
Source: 0001493152-25-019793
Chunk: 0

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-10-28
Form: PRER14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

(Amendment No. 1)</div>

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☒ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

<div align='center'>JUPITER NEUROSCIENCES, INC.

(Name of Registrant as Specified In Its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

☒ No fee required

☐ Fee paid previously with preliminary materials:

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

<div align='center'>EXPLANATORY NOTE</div>

This Amendment No. 1 to Schedule 14A (this “ Amended Proxy Statement”) amends and restates in its entirety the Preliminary Proxy Statement on Schedule 14A of Jupiter Neurosciences, Inc. (the “ Company”) that was originally filed with the Securities and Exchange Commission (the “ SEC”) on October 17, 2025 (the “ Original Proxy Statement”).

The purpose of this Amended Proxy Statement is (i) to reschedule the date of the Company’s 2025 virtual Annual Meeting of Stockholders (the “ Annual Meeting”), originally scheduled to take place on December 12, 2025, to December 19, 2025, and (ii) to include a proposal to approve, for purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(d), the potential issuance of shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock”), in excess of 19.99% or more of the Company’s issued and outstanding Common Stock of up to $20 million of securities pursuant to a Standby Equity Purchase Agreement (the “ SEPA”) with YA II